63 related articles for article (PubMed ID: 2602627)
1. [Effect of a single dose of nifedipine on the CO transfer capacity in patients with scleroderma].
Orvoen-Frija E; Dore MF; Fiessinger JN; Rochemaure J
Rev Mal Respir; 1989; 6(6):525-9. PubMed ID: 2602627
[TBL] [Abstract][Full Text] [Related]
2. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
Finch MB; Dawson J; Johnston GD
Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
[TBL] [Abstract][Full Text] [Related]
3. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
[TBL] [Abstract][Full Text] [Related]
4. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
6. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
7. Diffusing capacity of the lung and nifedipine in systemic sclerosis.
Sfikakis PP; Kyriakidis M; Vergos C; Papazoglou S; Georgiakodis F; Toutouzas P; Sfikakis P
Arthritis Rheum; 1990 Nov; 33(11):1634-9. PubMed ID: 2242061
[TBL] [Abstract][Full Text] [Related]
8. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Steen V; Medsger TA
Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
[TBL] [Abstract][Full Text] [Related]
9. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
10. Transient effect of nifedipine on pulmonary hypertension of systemic sclerosis.
Fudman EJ; Kelling DG
J Rheumatol; 1985 Dec; 12(6):1191-2. PubMed ID: 4093929
[TBL] [Abstract][Full Text] [Related]
11. [Respiratory function profile in scleroderma. 20 cases (author's transl)].
Kleisbauer JP; Feliciano JM; Colonna J; Velardocchio JM; Laval P
Poumon Coeur; 1980; 36(6):371-6. PubMed ID: 7220421
[TBL] [Abstract][Full Text] [Related]
12. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
13. [Change of pulmonary diffusing capacity, membrane diffusing capacity and pulmonary capillary blood volume in patients with COPD and connective tissue disease at rest and post-exercise].
Chi L; Liu Y; Piao Z
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jun; 21(6):344-7. PubMed ID: 11326890
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
Steen VD; Lucas M; Fertig N; Medsger TA
J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
[TBL] [Abstract][Full Text] [Related]
15. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
16. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
18. Colchicine in the treatment of scleroderma.
Guttadauria M; Diamond H; Kaplan D
J Rheumatol; 1977; 4(3):272-6. PubMed ID: 926103
[TBL] [Abstract][Full Text] [Related]
19. [Arterial hypertension with secondary hyperaldosteronism, reversible by nifedipine, in systemic scleroderma].
Gouet D; Rouffineau J; Marechaud R; Thomas P; Pourrat O; Alcalay M; Bontoux D
Ann Med Interne (Paris); 1983; 134(8):736-8. PubMed ID: 6666913
[TBL] [Abstract][Full Text] [Related]
20. Effects of nifedipine on diffusing capacity and pulmonary capillary blood volume in chronic obstructive pulmonary disease. A controlled study.
Dujić Z; Tocilj J; Slavković V
Respiration; 1991; 58(3-4):186-91. PubMed ID: 1745853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
